tldrdailynews.com logo

AZ and Ionis' heart-disease drug flops in pivotal ATTR-CM trial

1 min read
Source: STAT
AZ and Ionis' heart-disease drug flops in pivotal ATTR-CM trial
Photo: STAT
TL;DR

AstraZeneca and Ionis reported that their heart-disease drug Wainua failed to outperform placebo in a pivotal trial for ATTR-CM (transthyretin-mediated amyloid cardiomyopathy), not reducing cardiovascular death or clinical events, and the news pushed both companies' shares down in premarket trading.

Topics:businessbiotech#astrazeneca#attr-cm#biotech#clinical-trial-failure#ionis-pharmaceuticals#transthyretin-mediated-amyloid-cardiomyopathy
Share this article
  1. AstraZeneca, Ionis report major trial failure with heart disease drug  STAT
  2. AstraZeneca stock drops 9% after heart drug trial miss deals rare blow to pharma powerhouse  CNBC
  3. AstraZeneca, Ionis Stocks Stumble After Heart Drug Fails Key Trial  WSJ
  4. AstraZeneca's Wainua fails key heart disease trial, shares tumble  Reuters
  5. IONS Stock Heads Toward Biggest Single-Day Slump In Over 5 Years – Retail Calls It ‘Opportunity Of A Lifetime’  Yahoo Finance

Want the full story? Read the original reporting

Read on STAT